A Case of Multisystem Inflammatory Syndrome in Children (MIS-C) with Acute Myocarditis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
After initial reports of multisystem inflammatory syndrome in children (MIS-C) in April 2020 in Europe, this disease has been known to occur in children with recent history of coronavirus disease 2019 (COVID-19) and most cases have been reported in Europe and the Unites States of America. We report a case of a 14-year-old girl who was diagnosed with MIS-C with acute myocarditis and successfully treated with intravenous immunoglobulin (IVIG), methylprednisolone, and anakinra. At initial presentation, she had persistent high fever, generalized rash, generalized swelling, abdominal pain, and low blood pressure. She showed a remarkably elevated level of inflammation and cardiac enzyme markers and had a previous history of COVID-19 5 weeks before the initial presentation. After extensive work up, other infectious and non-infectious causes were excluded. She was diagnosed with MIS-C and initially treated with IVIG and high-dose methylprednisolone; however, despite treatment, her heart function deteriorated and coronary artery dilatation progressed. Therefore, anakinra, an interleukin-1 receptor antagonist, was administered on hospital day 6, after which her cardiac function exhibited improvement. She was discharged on hospital day 19 without any symptoms, and follow-up echocardiography after 1 month revealed fully recovered heart function with normal coronary arteries.
Abstract
After initial reports of multisystem inflammatory syndrome in children (MIS-C) in April 2020 in Europe, this disease has been known to occur in children with recent history of coronavirus disease 2019 (COVID-19) and most cases have been reported in Europe and the Unites States of America. We report a case of a 14-year-old girl who was diagnosed with MIS-C with acute myocarditis and successfully treated with intravenous immunoglobulin (IVIG), methylprednisolone, and anakinra. At initial presentation, she had persistent high fever, generalized rash, generalized swelling, abdominal pain, and low blood pressure. She showed a remarkably elevated level of inflammation and cardiac enzyme markers and had a previous history of COVID-19 5 weeks before the initial presentation. After extensive work up, other infectious and non-infectious causes were excluded. She was diagnosed with MIS-C and initially treated with IVIG and high-dose methylprednisolone; however, despite treatment, her heart function deteriorated and coronary artery dilatation progressed. Therefore, anakinra, an interleukin-1 receptor antagonist, was administered on hospital day 6, after which her cardiac function exhibited improvement. She was discharged on hospital day 19 without any symptoms, and follow-up echocardiography after 1 month revealed fully recovered heart function with normal coronary arteries.
참고문헌 (20)
- Lee PI, "Are children less susceptible to COVID-19?", J Microbiol Immunol Infect, 53, pp.371~372 (2020)
- Epidemiology Working Group for NCIP Epidemic Response, "Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China", Zhonghua Liu Xing Bing Xue Za Zhi, 41, pp.145~151 (2020)
- Riphagen S, "Hyperinflammatory shock in children during COVID-19 pandemic", Lancet, 395, pp.1607~1608 (2020)
- Verdoni L, "An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study", Lancet, 395, pp.1771~1778 (2020)
- "Press release: COVID-19 status in Korea (May 25th, regular briefing)" (2020)[URL]
- Henderson LA, "American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1", Arthritis Rheumatol, 72, pp.1791~1805 (2020)
- Choe YJ, "Surveillance of COVID-19-associated multisystem inflammatory syndrome in children, South Korea", Emerg Infect Dis, 27, pp.1196~1200 (2021)
- World Health Organization (WHO), "Multisystem inflammatory syndrome in children and adolescents with COVID-19: scientific brief, 15 May 2020", WHO, ~ (2020)
- "Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19)" (2020)[URL]
- Haena Kim, "Multisystem Inflammatory Syndrome in Children Related to COVID-19: the First Case in Korea", Journal of Korean Medical Science, 35(43), pp.1~8 (2020), 대한의학회[DOI]
- Henderson LA, "American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2", Arthritis Rheumatol, 73, pp.e13~e29 (2021)
- Feldstein LR, "Multisystem inflammatory syndrome in US children and adolescents", N Engl J Med, 383, pp.334~346 (2020)
- Belhadjer Z, "Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic", Circulation, 142, pp.429~436 (2020)
- Jiang L, "COVID-19 and multisystem inflammatory syndrome in children and adolescents", Lancet Infect Dis, 20, pp.e276~e288 (2020)
- Abrams JY, "Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review", J Pediatr, 226, pp.45~54.e1 (2020)
- Consiglio CR, "The immunology of multisystem inflammatory syndrome in children with COVID-19", Cell, 183, pp.968~981.e7 (2020)
- Lee Joon Kee, "소아 다기관 염증 증후군", Pediatric Infection and Vaccine, 28(2), pp.66~81 (2021), 대한소아감염학회[DOI]
- Son MB, "Multisystem inflammatory syndrome in children - Initial therapy and outcomes", N Engl J Med, 385, pp.23~34 (2021)
- Ouldali N, "Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children", JAMA, 325, pp.855~864 (2021)
- Guillaume MP, "Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm", Cardiol Young, 28, pp.739~742 (2018)